NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

促血紅細胞生長素製劑市場成長機會·成長預測 (2021-2028年):產品類型 (紅血球生成素Alpha·紅血球生成素β·Darbepoetin Alpha·其他)·用途 (血液·腎障礙·癌症·其他)、各地區

Erythropoietin Drugs Market by Product Type (Epoetin-Alfa, Epoetin-Beta, and Darbepoetin-Alfa, Others) and Application (Hematology, Kidney Disorder, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2021-2028

出版商 Allied Market Research 商品編碼 1017292
出版日期 內容資訊 英文 165 Pages
商品交期: 2-3個工作天內
價格
促血紅細胞生長素製劑市場成長機會·成長預測 (2021-2028年):產品類型 (紅血球生成素Alpha·紅血球生成素β·Darbepoetin Alpha·其他)·用途 (血液·腎障礙·癌症·其他)、各地區 Erythropoietin Drugs Market by Product Type (Epoetin-Alfa, Epoetin-Beta, and Darbepoetin-Alfa, Others) and Application (Hematology, Kidney Disorder, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2021-2028
出版日期: 2021年05月28日內容資訊: 英文 165 Pages
簡介

促血紅細胞生長素製劑的市場規模在預測期間內預計將以5.7%的年複合成長率推移,從2020年的92億4312萬美元,成長到2028年144億1459萬美元的規模。

越來越多的癌症、HIV 和 ESRD 治療導致的貧血患者、有利的報銷計劃以及 EPO 生物仿製藥商業化的增加等因素正在推動市場的增長。動脈高血壓、缺鐵和流感樣綜合徵等副作用,以及更長的治療週期(4-6 週)是市場進一步增長的障礙,但許多生物仿製藥的興起和認知度的提高有望促進市場增長。

本報告提供全球促血紅細胞生長素製劑的市場調查,彙整市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,臨床試驗趨勢,市場規模的轉變·預測,產品·用途·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義·範圍
  • EPO藥的臨床試驗
  • 市場佔有率分析
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19:影響分析

第4章 市場分析·預測:各產品

  • 紅血球生成素Alpha
  • 紅血球生成素β
  • Darbepoetin Alpha
  • 其他
    • 主要趨勢·成長機會
    • 市場規模·預測
    • 市場分析:各國

第5章 市場分析·預測:各用途

  • 血液
  • 腎障礙(ESRD·透析)
  • 癌症
  • 其他
    • 市場規模·預測
    • 市場分析:各國

第6章 市場分析·預測:地區·各主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲
    • 主要趨勢·成長機會
    • 市場規模·預測

第7章 企業簡介

  • AMGEN INC.
  • JOHNSON AND JOHNSON
  • ROCHE DIAGNOSTICS
  • HOSPIRA INC.
  • LG LIFE SCIENCES LTD.
  • BIOCON
  • INTAS PHARMACEUTICALS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • RANBAXY LABORATORIES LTD.
  • CELLTRION, INC
目錄
Product Code: A00001

The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $ 14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin-alfa, epoetin-beta, darbepoetin-alfa, epoetin-omega, and epoetin-delta.

Rise in number of patients suffering from anemic conditions induced due to cancer, HIV and ESRD treatment, favorable reimbursements, and increase in commercialization of EPO biosimilars are the major factors for the market growth. However, side effects such as arterial hypertension, iron deficiency, influenza-like syndrome, and longer treatment period (4-6 weeks) hampers growth of erythropoietin drugs market. Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth. Furthermore, commercialization patterns for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and awareness regarding benefits of EPO therapeutics contribute toward growth of erythropoietin drugs market.

The global erythropoietin drugs market is segmented into product type, application, and region. On the basis of product type, the market is categorized into epoetin-alfa, epoetin-beta, darbepoetin alfa. By application, it is classified into anemia, kidney disorders, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of erythropoietin used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin alfa

By Application

  • Anemia
  • Kidney Disorders
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Amgen Inc.
  • Biocon,
  • Celltrion, Inc.
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Hospira Inc.
  • Intas Pharmaceuticals
  • LG Life Sciences Ltd.
  • Roche
  • Ranbaxy Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Primary research
    • 1.4.2.Secondary Research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Clinical trials for EPO drug
  • 3.3.Market share analysis, 2020
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increasing number cases: including cancer,HIV, kidney disease and anaemia
      • 3.4.1.2.Growing trends of commercialization for erythropoietin biosimilars
      • 3.4.1.3.Increasing level of awareness about the benefits of EPO therapeutics
    • 3.4.2.Restraints
      • 3.4.2.1.Unaffordability of therapeutics
      • 3.4.2.2.Longer duration of treatments
      • 3.4.2.3.Adverse amount of side effects
    • 3.4.3.Opportunities
      • 3.4.3.1.Commercialization of Darbepoetin alfa biosimilar
      • 3.4.3.2.Achieving Economies of scale across developed region with biosimilar version of EPO
  • 3.5.Impact of Covid-19 on Erythropoietin Drug Market

CHAPTER 4:GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS

  • 4.1.Epoetin-alfa
    • 4.1.1.Key market trends and opportunities
    • 4.1.2.Market size and forecast
    • 4.1.3.Market analysis, by country
  • 4.2.Epoetin-beta
    • 4.2.1.Key market trends and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Darbepoetin-alfa
    • 4.3.1.Key market trends and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Other
    • 4.4.1.Key market trends and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS

  • 5.1.Hematology
    • 5.1.1.Market size and forecast
    • 5.1.2.Market analysis, by country
  • 5.2.Kidney Disorders (ESRD and Dialysis)
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Cancer
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Others
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY

  • 6.1.North America
    • 6.1.1.Key market trends & opportunities
    • 6.1.2.Market size and forecast
  • 6.2.Europe
    • 6.2.1.Key market trends & opportunities
    • 6.2.2.Market size and forecast
  • 6.3.Asia-Pacific
    • 6.3.1.Key market trends & opportunities
    • 6.3.2.Market size and forecast
  • 6.4.LAMEA
    • 6.4.1.Key market trends & opportunities
    • 6.4.2.Market size and forecast

CHAPTER 7:COMPANY PROFILES

  • 7.1.AMGEN INC.
    • 7.1.1.Company overview
    • 7.1.2.Amgen Inc. snapshot
    • 7.1.3.Operating Business Segment
    • 7.1.4.Financial performance
  • 7.2.JOHNSON AND JOHNSON
    • 7.2.1.Company overview
    • 7.2.2.Johnson & Johnson snapshot
    • 7.2.3.Operating Business Segment overview
    • 7.2.4.Financial performance
  • 7.3.ROCHE DIAGNOSTICS
    • 7.3.1.Company overview
    • 7.3.2.Roche Diagnostics snapshot
    • 7.3.3.Operating Business Segment Overview
    • 7.3.4.Financial performance
  • 7.4.HOSPIRA INC.
    • 7.4.1.Company overview
    • 7.4.2.Hospira Inc. snapshot
    • 7.4.3.Operating business segment
    • 7.4.4.Financial performance
    • 7.4.5.Key Strategies move & development
  • 7.5.LG LIFE SCIENCES LTD.
    • 7.5.1.Company overview
    • 7.5.2.LG Life Sciences Ltd. snapshot
    • 7.5.3.Operating Business segment overview
    • 7.5.4.Financial performance
  • 7.6.BIOCON
    • 7.6.1.Company overview
    • 7.6.2.Biocon snapshot
    • 7.6.3.Operating Business Segment Overview
    • 7.6.4.Financial performance
    • 7.6.5.Key Strategies move and development
  • 7.7.INTAS PHARMACEUTICALS
    • 7.7.1.Company overview
    • 7.7.2.Intas Pharmaceuticals snapshot
    • 7.7.3.Operating Business Segment Overview
    • 7.7.4.Financial performance
  • 7.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 7.8.1.Company overview
    • 7.8.2.Teva Pharmaceutical Industries Ltd. snapshot
    • 7.8.3.Operating business segment overview
    • 7.8.4.Financial performance
  • 7.9.RANBAXY LABORATORIES LTD.
    • 7.9.1.Company overview
    • 7.9.2.Ranbaxy Laboratories Ltd. snapshot
    • 7.9.3.Operating business segment overview
    • 7.9.4.Financial performance
  • 7.10.CELLTRION, INC
    • 7.10.1.Company overview
    • 7.10.2.Celltrion, Inc. snapshot
    • 7.10.3.Financial performance

LIST OF TABLES

  • TABLE 01.CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
  • TABLE 02.GLOBAL ERYTHROPOIETIN DRUG MARKET BY PRODUCT TYPES, 2020-2028($MILLION)
  • TABLE 03.GLOBAL ERYTHROPOIETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
  • TABLE 04.GLOBAL ERYTHROPOIETIN BETA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
  • TABLE 05.GLOBAL DARBEPOETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
  • TABLE 06.GLOBAL OTHER DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
  • TABLE 07.GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS, 2020-2028($MILLION)
  • TABLE 08.GLOBAL HEMATOLOGY APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
  • TABLE 09.GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
  • TABLE 10.GLOBAL CANCER APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
  • TABLE 11.GLOBAL OTHERS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
  • TABLE 12.GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2020 - 2020 ($MILLION)
  • TABLE 13.NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 - 2020 ($MILLION)
  • TABLE 15.EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 - 2020 ($MILLION)
  • TABLE 17.ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 - 2020 ($MILLION)
  • TABLE 18.LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 - 2020 ($MILLION)
  • TABLE 19.AMGEN INC. SNAPSHOT
  • TABLE 20.AMGEN INC. OPERATING BUSINESS SEGMENT
  • TABLE 21.JOHNSON & JOHNSON SNAPSHOT
  • TABLE 22.JOHNSON AND JOHNSON OPERATING SEGEMENTS
  • TABLE 23.ROCHE DIAGNOSTICS SNAPSHOT
  • TABLE 24.ROCHE DIAGNOSTICS OPERATING SEGEMENTS
  • TABLE 25.HOSPIRA INC. SNAPSHOT
  • TABLE 26.HOSPIRA INC. OPERATING SEGEMENTS
  • TABLE 27.LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
  • TABLE 28.LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
  • TABLE 29.BIOCON SNAPSHOT
  • TABLE 30.BIOCON OPERATING SEGEMENTS
  • TABLE 31.INTAS PHARMACEUTICALS SNAPSHOT
  • TABLE 32.INTAS PHARMACEUTICALS OPERATING SEGEMENTS
  • TABLE 33.TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
  • TABLE 34.TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
  • TABLE 35.RANBAXY LABORATORIES LTD. SNAPSHOT
  • TABLE 36.CELLTRION, INC. SNAPSHOT

LIST OF FIGURES

  • FIGURE 01.GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
  • FIGURE 02.MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2020)
  • FIGURE 03.FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2020)
  • FIGURE 04.FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2020)
  • FIGURE 05.SWOT ANALYSIS OF AMGEN INC.
  • FIGURE 06.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2020)
  • FIGURE 07.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS(2020)
  • FIGURE 08.SWOT ANALYSIS OF JOHNSON & JOHNSON
  • FIGURE 09.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2020)
  • FIGURE 10.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2020)
  • FIGURE 11.SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIGURE 12.FINANCIAL REVENUE OF HOSPIRA INC. BY GEOGRAPHY (2020)
  • FIGURE 13.FINANCIAL REVENUE OF HOSPIRA INC. BY BUSINESS UNITS (2020)
  • FIGURE 14.SWOT ANALYSIS OF HOSPIRA INC.
  • FIGURE 15.NET REVENUE GENERATION (2011-2020)
  • FIGURE 16.SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
  • FIGURE 17.REVENUE GENERATED BY BUSINESS UNITS (2020)
  • FIGURE 18.SWOT ANALYSIS OF BIOCON
  • FIGURE 19.SWOT ANALYSIS OF INTAS PHARMACEUTICALS
  • FIGURE 20.NET REVENUE GENERATION BY GEOGRAPHY (2020)
  • FIGURE 21.NET REVENUE GENERATION BY BUSINESSES (2020)
  • FIGURE 22.SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • FIGURE 23.KEY FINANCIALS OF RANBAXY LABORATORIES LIMITED BY GEOGRAPHY (2014)
  • FIGURE 24.SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
  • FIGURE 25.NET PROFIT DURING 2011-2020
  • FIGURE 26.SWOT ANALYSIS OF CELLTRION, INC.